Jen Smith

Writer at Freelance

Recovering sportswriter. Journalism professor at the University of Kentucky. Mom. Wife. Lucky girl.

Featured in: Favicon

bbc.co.uk

msn.com

dailymail.co.uk Favicon

cbsnews.com Favicon

insider.com Favicon

investopedia.com Favicon

flipboard.com Favicon

miamiherald.com Favicon

huffingtonpost.co.uk Favicon

audioboom.com + 112 more

Articles

Adding Perioperative Systemic Therapy to CRS-HIPEC Improves PFS, Not OS

1 week ago | shorturl.at | Jen Smith

Adding perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can improve some outcomes in patients with resectable colorectal peritoneal metastases, according to research presented at the ASCO Annual Meeting 2025. This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).
Novel MCED Test May Detect Multiple Cancer Types in High-Risk Patients

1 week ago | shorturl.at | Jen Smith

A novel multi-cancer early detection (MCED) test can detect multiple cancer types in patients with obesity, including cancers for which no screening programs currently exist, according to research presented at the ASCO Annual Meeting 2025. The MCED test, which is being developed by Harbinger Health, uses methylation patterns of cell-free circulating tumor DNA (ctDNA) in the blood to detect cancer. The reflex test system employs a 2-step approach.
Adding Perioperative Systemic Therapy to CRS-HIPEC Improves PFS, Not OS

1 week ago | cancertherapyadvisor.com | Jen Smith

Adding perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can improve some outcomes in patients with resectable colorectal peritoneal metastases, according to research presented at the ASCO Annual Meeting 2025. This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).
Combo Deemed New Standard of Care for BRAF-Mutant, Metastatic Colorectal Cancer

1 week ago | shorturl.at | Jen Smith

Encorafenib plus cetuximab and mFOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) outperformed standard first-line treatment in a phase 3 trial of patients with BRAF V600E-mutated, metastatic colorectal cancer, according to results presented at the ASCO Annual Meeting 2025.1In this trial — BREAKWATER (NCT04607421) — encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival (PFS) and overall survival (OS) when compared to standard chemotherapy.
Canadienses hacen boicot a Estados Unidos. ¿Siguen siendo bienvenidos los viajeros estadounidenses en Canadá?

1 week ago | local3news.com | Jen Smith

La bucólica región de Cantons-de-l’Est, al sur de Quebec y cubierta de viñedos, tiene un mensaje para los estadounidenses: vengan a darse un abrazo. El 26 de mayo, la oficina de turismo de la región publicó un video promocional en el que se ve a un turista anglófono que admite tímidamente ser estadounidense y recibe un fuerte abrazo de la recepcionista de un hotel francófono.
HHS Sets Targets for Most-Favored-Nation Drug Pricing

1 week ago | pulmonologyadvisor.com | Jen Smith

The US Department of Health and Human Services (HHS) announced that it has taken the first step toward implementing most-favored-nation pricing for prescription drugs, in compliance with a recent executive order.1 HHS and the Centers for Medicare & Medicaid Services (CMS) have identified targets that pharmaceutical manufacturers will be expected to meet to satisfy the requirements of the order.
Trump Aims to Reduce Drug Prices With “Most-Favored-Nation” Policy

2 weeks ago | dermatologyadvisor.com | Jen Smith

Today, President Donald Trump signed an executive order aimed at reducing the cost of prescription drugs.1 The order states that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest price. “Americans will no longer be forced to pay almost 3 times more [than other countries] for the exact same medicines, often made in the exact same factories,” the executive order states.
Certain Early-Onset Cancers Are on the Rise in the US

2 weeks ago | rheumatologyadvisor.com | Jen Smith

The incidence of early-onset cancers in the United States is not rising overall, but rates of certain cancers are increasing among younger patients, new data suggest. Researchers reported these findings in Cancer Discovery. “For the most common of these cancers, the increases do not seem to only be occurring among younger ages, implicating increased cancer risk across the age range. In addition, there were not concomitant increases in mortality for most cancer types with increasing incidence rates.
Most Americans Surveyed Do Not Support Trump’s Cuts to Federal Health Agencies

2 weeks ago | ophthalmologyadvisor.com | Jen Smith

Most Americans surveyed said they do not support the Trump administration’s recent cuts to staff and spending at federal health agencies. The survey was conducted by KFF and included a nationally representative sample of 1380 US adults. Overall, 61% of survey respondents said they oppose major cuts to spending and staff at federal health agencies.
Cuts to Medicare Reimbursement May Force Practices to Close

2 weeks ago | medicalbag.com | Jen Smith

Cuts to Medicare reimbursement for radiation therapy could prevent cancer patients from accessing care and force practices to downsize or close, according to a survey conducted by the American Society for Radiation Oncology (ASTRO).1 ASTRO surveyed 675 US-based, non-emeritus radiation oncologists about the potential impacts of cuts to Medicare reimbursement, and 96% of respondents said cuts would impede patients’ access to care.